Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib Phase I/II in Myelofibrosis
NCT01423058Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2011
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of momelotinib dihydrochloride in myelofibrosis (MF), sponsored by GSK. Primary endpoints: Safety and Tolerability at 6 months, Maximum Tolerated Dose at 6 months and 2 more. Started Aug 2011; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01423058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423058.